Literature DB >> 20364288

Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges.

Raymond Oppong1, Joanna Coast, Kerry Hood, Jacqui Nuttall, Richard D Smith, Christopher C Butler.   

Abstract

The objectives of this study were to estimate the resource use and cost of treating acute cough/lower respiratory tract infection (acute cough/LRTI) in 13 European countries, to explore reasons for differences in cost and to document the challenges that researchers face when collecting information on cost alongside multinational studies. Data on resource use and cost were collected alongside an observational study in 14 primary care networks across 13 European countries and a mean cost was generated for each network. The results show that the mean cost (standard deviation) of treating acute cough/LRTI in Europe ranged from euro23.88 (34.67) in Balatonfüred (Hungary) to euro116.47 (34.29) in Jonkoping (Sweden). The observed differences in costs were statistically significant (P < 0.01). Major cost drivers include general practitioner visits and drug costs in all networks, whilst differences in health systems and regional factors could account for differences in cost between networks. The major barrier to conducting multinational cost studies are barriers associated with identifying cost information.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20364288     DOI: 10.1007/s10198-010-0239-1

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  29 in total

1.  Centre-specific or average unit costs in multi-centre studies? Some theory and simulation.

Authors:  M Raikou; A Briggs; A Gray; A McGuire
Journal:  Health Econ       Date:  2000-04       Impact factor: 3.046

Review 2.  Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence.

Authors:  P Ball; F Baquero; O Cars; T File; J Garau; K Klugman; D E Low; E Rubinstein; R Wise
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

3.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Authors:  Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

4.  Collecting unit cost data in multicentre studies. Creating comparable methods.

Authors:  Sarah Wordsworth; Anne Ludbrook; Fergus Caskey; Alison Macleod
Journal:  Eur J Health Econ       Date:  2005-03

5.  Herbal medicine in Europe--relaxing regulatory standards.

Authors:  Peter A G M De Smet
Journal:  N Engl J Med       Date:  2005-03-24       Impact factor: 91.245

6.  Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.

Authors:  Shelby D Reed; Kevin J Anstrom; Ameet Bakhai; Andrew H Briggs; Robert M Califf; David J Cohen; Michael F Drummond; Henry A Glick; Ari Gnanasakthy; Mark A Hlatky; Bernie J O'Brien; Frank M Torti; Anastasios A Tsiatis; Andrew R Willan; Daniel B Mark; Kevin A Schulman
Journal:  Am Heart J       Date:  2005-03       Impact factor: 4.749

7.  Resource costing for multinational neurologic clinical trials: methods and results.

Authors:  K Schulman; J Burke; M Drummond; L Davies; P Carlsson; J Gruger; A Harris; C Lucioni; R Gisbert; T Llana; E Tom; B Bloom; R Willke; H Glick
Journal:  Health Econ       Date:  1998-11       Impact factor: 3.046

8.  Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models.

Authors:  Andrea Manca; Nigel Rice; Mark J Sculpher; Andrew H Briggs
Journal:  Health Econ       Date:  2005-05       Impact factor: 3.046

Review 9.  Primary care diabetes in Hungary.

Authors:  Imre Rurik
Journal:  Prim Care Diabetes       Date:  2007-08-13       Impact factor: 2.459

10.  Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries.

Authors:  C C Butler; K Hood; T Verheij; P Little; H Melbye; J Nuttall; M J Kelly; S Mölstad; M Godycki-Cwirko; J Almirall; A Torres; D Gillespie; U Rautakorpi; S Coenen; H Goossens
Journal:  BMJ       Date:  2009-06-23
View more
  18 in total

1.  The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries.

Authors:  Raymond Oppong; Billingsley Kaambwa; Jacqueline Nuttall; Kerenza Hood; Richard D Smith; Joanna Coast
Journal:  Eur J Health Econ       Date:  2011-11-05

2.  Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance.

Authors:  Raymond Oppong; Richard D Smith; Paul Little; Theo Verheij; Christopher C Butler; Herman Goossens; Samuel Coenen; Michael Moore; Joanna Coast
Journal:  Br J Gen Pract       Date:  2016-07-11       Impact factor: 5.386

3.  Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions.

Authors:  Raymond Oppong; Mark Jit; Richard D Smith; Christopher C Butler; Hasse Melbye; Sigvard Mölstad; Joanna Coast
Journal:  Br J Gen Pract       Date:  2013-07       Impact factor: 5.386

4.  Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT.

Authors:  Andrew I Gumley; Simon Bradstreet; John Ainsworth; Stephanie Allan; Mario Alvarez-Jimenez; Maximillian Birchwood; Andrew Briggs; Sandra Bucci; Sue Cotton; Lidia Engel; Paul French; Reeva Lederman; Shôn Lewis; Matthew Machin; Graeme MacLennan; Hamish McLeod; Nicola McMeekin; Cathy Mihalopoulos; Emma Morton; John Norrie; Frank Reilly; Matthias Schwannauer; Swaran P Singh; Suresh Sundram; Andrew Thompson; Chris Williams; Alison Yung; Lorna Aucott; John Farhall; John Gleeson
Journal:  Health Technol Assess       Date:  2022-05       Impact factor: 4.106

5.  C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT.

Authors:  Nick A Francis; David Gillespie; Patrick White; Janine Bates; Rachel Lowe; Bernadette Sewell; Rhiannon Phillips; Helen Stanton; Nigel Kirby; Mandy Wootton; Emma Thomas-Jones; Kerenza Hood; Carl Llor; Jochen Cals; Hasse Melbye; Gurudutt Naik; Micaela Gal; Deborah Fitzsimmons; Mohammed Fasihul Alam; Evgenia Riga; Ann Cochrane; Christopher C Butler
Journal:  Health Technol Assess       Date:  2020-03       Impact factor: 4.014

6.  Cough: impact, beliefs, and expectations from a national survey.

Authors:  Roberto W Dal Negro; Massimiliano Mazzolini; Paola Turco; Alessandro Zanasi
Journal:  Multidiscip Respir Med       Date:  2016-09-27

7.  Increased health service use for asthma, but decreased for COPD: Northumbrian hospital episodes, 2013-2014.

Authors:  I Shiue
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-15       Impact factor: 3.267

8.  How patients' experiences of respiratory tract infections affect healthcare-seeking and antibiotic use: insights from a cross-sectional survey in rural Anhui, China.

Authors:  Mengjie Diao; Xingrong Shen; Jing Cheng; Jing Chai; Rui Feng; Panpan Zhang; Rongyao Zhou; Helen Lambert; Debin Wang
Journal:  BMJ Open       Date:  2018-02-03       Impact factor: 2.692

9.  Usefulness of C-reactive protein testing in acute cough/respiratory tract infection: an open cluster-randomized clinical trial with C-reactive protein testing in the intervention group.

Authors:  Elena Andreeva; Hasse Melbye
Journal:  BMC Fam Pract       Date:  2014-05-02       Impact factor: 2.497

10.  Obesity and risk of respiratory tract infections: results of an infection-diary based cohort study.

Authors:  Livia Maccioni; Susanne Weber; Magdeldin Elgizouli; Anne-Sophie Stoehlker; Ilona Geist; Hans-Hartmut Peter; Werner Vach; Alexandra Nieters
Journal:  BMC Public Health       Date:  2018-02-20       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.